+ 34 986 812 316

CNIO-Lilly Epigenetics Lab
Melchor Fernandez Almagro, 3. 28029 Madrid. SPAIN

Epigenetics, cancer, chromatin, transcription, histone modifications


Cancer cell lines, xenograft, animal models of cancer


RNA-seq, ChIP-seq, Chem-seq, xenograft

Collaborations outside COST

Eli Lilly and company

Short description of ongoing research projects

Eli Lilly and CNIO are collaborating on the identification and validation of novel targets in cancer epigenetics. Our Section is funded through a research contract with Eli Lilly and focuses on the identification of small molecular weight molecules that are able to modulate the epigenome of malignant cells, and ultimately block the growth and spread of tumours. Potential targets are being validated in vitro and in vivo using animal models developed at the CNIO. Furthermore, we are currently setting up biochemical and cell-based assays with the aim of understanding the mechanism of action of such targets at the molecular level.

  1. Barrero, M. J. Epigenetics, Stem Cell Pluripotency and Differentiation. (2015) Principles of Stem Cell Biology and Cancer, Future Applications and Therapeutics. doi: 10.1002/9781118670613.ch2
  2. Barrero MJ, Sese B, Kuebler B, Bilic J, Boue S, Martí M, Belmonte JC. Macro Histone Variants Preserve Cell Identity by Preventing the Gain of H3K4me2 during Reprogramming to Pluripotency. (2013) Cell Reports. Mar 27. doi:pii: S2211-1247(13)00105-8. 10.1016/j.celrep.2013.02.029.
  3. Nock A., Ascano J.A., Barrero M.J. and Malik S. Mediator-regulated transcription through the +1 nucleosome. (2012) Molecular Cell. 48(6):837-48.
  4. Barrero M.J., Berdasco M, Paramonov I, Bilic J, Vitaloni M, Esteller M and Izpisua Belmonte JC. DNA hypermethylation in somatic cells correlates with higher reprogramming efficiency. (2012) Stem Cells. doi: 10.1002/stem
  5. Barrero M.J. The stability of the induced epigenetic programs. (2012) Comparative and Functional Genomics. 2012:434529.
Other activities of potential interest to others

Cost UE